If you’ve decided you need to incorporate phenotypic screening into your discovery program and you know that one of the new generation of automation platforms is the way forward, what factors should influence your choice?
Automation, miniaturization, cell based assays and 3D cell culture
A main presentation track at SLAS2018 entitled "Cellular Technologies" will include the session "Development of Cellular Models for Phenotypic Screening," chaired by Kristen Brennand, Ph.D., New York Stem Cell Foundation-Robertson Investigator and Associate Professor, Departments of Genetics and Genomics, Neuroscience and Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY. We spoke to Dr. Brennand about the key topics, highlighted trends, and target audience for the talks and presenters he has prepared.
Phenotypic screening is back, with exciting implications for the discovery of new and more effective drugs. The reason? Constantly improving cellular technologies and instrumentation, and drug discovery and development programs bringing us closer to truly realizing the potential of precision medicine.
Now that phenotypic screening is well and truly back, how do you take advantage of its many benefits, especially if you’ve already made a considerable commitment to target-based screening? The simple answer is: you combine the two.